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Glaucoma is a progressive neuropathy characterized by loss of vision as a result of 
retinal ganglion cell (RGC) death. There are no effective neuroprotectants to treat this 
disorder. Brain-derived neurotrophic factor (BDNF) is well known to transiently delay 
RGC death in the ocular hypertentive eyes. The central nervous system-specific 
leucine-rich repeat protein LINGO-1 contributes to the negative regulation to some 
trophic pathways. We thereby examined whether BDNF combined with LINGO-1 
antagonists can promote long-term RGC survival after ocular hypertension. In this 
study, intraocular pressure was elevated in adult rats using an argon laser to 
photocoagulate the episcleral and limbal veins. BDNF alone shows slight 
neuroprotection to RGCs after a long-term progress of 4 weeks following the 
induction of ocular hypertension. However, combination of BDNF and LINGO-1-Fc 
prevents RGC death in the same condition. We further identified that 1) LINGO-1 
was co-expressed with BDNF receptor, TrkB in the RGCs, and 2) BDNF combined 
with LINGO-1-Fc activated more TrkB in the injured retina compared to BDNF alone. 
These results indicate that the combination of BDNF with LINGO-1 antagonist can 
provide long-term protection for RGCs in a chronic ocular hypertension model. TrkB 
may be the predominant mediator of this neuroprotection. 
 
Keywords: Ocular hypertension; Neural cells; Neuronal survival; Neurotrophic 
factors; TrkB 
 
 
 
 
Glaucoma represents a group of neurodegenerative diseases characterized by 
structural damage to the optic nerve and slow, progressive death of retinal ganglion 
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cells (RGCs) (Quigley et al., 1995). Although the most important trigger for 
progression of glaucomatous damage is an elevation of intraocular pressure (IOP), the 
exact mechanism remains unknown. Current standard therapy for glaucoma is to 
lower the IOP by medication or surgery that may delay disease progression but does 
not alter RGC loss and axon degeneration. Therefore, treatment of glaucomatous 
neuropathy requires the preservation, protection, and rescue of RGCs. Although 
several approaches for neuroprotection have been described including the use of 
neurotrophins (Cui et al., 1998), no effective clinical neuroprotectants are available. 
Neurotrophic agents have been implicated in survival- and growth-promoting 
activity in the central nerve system (CNS). Brain-derived neurotrophic factor (BDNF) 
is an important survival factor for RGCs. BDNF rescues RGCs from death after optic 
nerve axotomy (Yan et al., 1999; Zhang et al., 2005; Mansour-Robaey et al., 1994; 
Mey and Thanos, 1993) and in cell culture (Johnson et al., 1986). Exogenously 
applied BDNF can delay the death of RGCs in animal glaucoma models (Ko et al., 
2001; Quigley et al., 2000). However, a series of studies showed that BDNF did not 
rescue all RGCs after optic nerve axotomy and only delayed RGC death (Mansour-
Robaey et al., 1994; Mey and Thanos, 1993; Peinado-Ramon et al., 1996; Klocker et 
al., 1998). Even repeated intravitreal injections of BDNF, or persistent availability of 
bioactive BDNF did not promote long-term survival of RGCs after axotomy 
(Mansour-Robaey et al., 1994; Di et al., 1998; Isenmann et al., 1998). The protective 
effect of exogenous BDNF or overexpression of BDNF gene on RGCs was also 
limited in a chronic glaucoma model (Martin et al., 2003; Ko et al., 2001). A clearer 
mechanistic understanding of the limited neuroprotection of BDNF can be crucial for 
the development of treatments for glaucoma.?
LINGO-1 is a leucine-rich repeat Ig-containing protein first identified as a 
critical component of Nogo receptor /p75 or TROY signaling complexes that prevent 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 4
axonal regeneration in the presence of myelin inhibitors in the CNS (Shao et al., 2005; 
Mi et al., 2004). LINGO-1 is specific to the CNS and functions as a negative regulator 
of axonal regeneration and neuronal survival. We previously found that blocking the 
function of LINGO-1 protected a major proportion of injured RGCs in rats with 
ocular hypertension (Fu et al., 2008a). LINGO-1 binds to the epidermal growth factor 
receptor to negatively regulates its activation (Inoue et al., 2007). We just identified 
that LINGO-1 binds with BDNF receptor, TrkB and inhibits TrkB activation in vitro 
and in the rat retinas (Fu QL et al., unpublished data). These data suggest that the 
negative regulatory functions of LINGO-1 may be involved in the limited 
neuroprotective effect of BDNF and it could be reversed after blocking the LINGO-1 
function. 
In this study, we investigated the combined neuroprotective effect of BDNF 
and a LINGO-1 antagonist, soluble LINGO-1 protein in a rat ocular hypertension 
model. We also investigated the involvement of TrkB activation with neuroprotection 
in this model. 
 
EXPERIMENTAL PROCEDURES 
Generation of recombinant LINGO-1-Fc 
LINGO-1-Fc protein (soluble LINGO-1) was prepared as described previously (Mi et 
al., 2004). Residues 1-532 of human LINGO-1 was fused to the hinge and Fc region 
of human IgG1, expressed in CHO cells and purified on Protein A Sepharose 
(Phamacia). The purified protein (> 95% pure) ran on SDS-PAGE with M
r
 = 90 kDa 
under reducing conditions and M
r
 = 180 kDa under non-reducing conditions. 
Recombinant human BDNF was purchased from Regeneron Pharmaceutical 
(Tarrytown, NY). 
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Animals 
Adult female Sprague-Dawley rats weighing approximately 250-280 g were reared in 
a temperature-controlled room on a 12-hour light–dark cycle in the Laboratory 
Animal Unit of The University of Hong Kong.  A total of 32 rats was used for the 
study of RGC survival (n = 8 for each group). The animal number is 4-5 for each 
group for the experiments on histochemistry and western blotting. All the 
experimental and animal handling procedures complied with the ARVO Statement for 
the Use of Animals in Ophthalmic and Vision Research and were also reviewed and 
approved by the Faculty Committee on the Use of Live Animals in Teaching and 
Research, The University of Hong Kong. The animals were anesthetized with 
intraperitoneal injection of ketamine (80 mg/kg, 10% alfasan, Woerden, Netherlands) 
and xylazine (8 mg/kg, 2% alfasan, Woerden, Netherlands) during the experiments 
and were euthanized with an overdose of pentobarbital sodium (150 mg/kg, Alcon-
Couvreur, Rijksweg, Puurs, Belgium). Alcaine 0.5% (Alcon-Couvreur, Rijksweg, 
Puurs, Belgium) was applied to the eyes before all operations and antiseptic eye drops 
(Tobres [Tobramycin 0.3%], Alcon-Couvreur, Rijksweg, Puurs, Belgium) were used 
to prevent infection after the treatment. Rimadyl (0.025mg/ml, Pfizer, NY, USA) in 
drinking water was used to relieve the pain for 7 days after the surgeries.  
 
Ocular hypertension model and treatments 
To induce experimental ocular hypertension, the rats received argon laser (Ultima 
2000SE Argon Laser, Coherent, Palo Alto, CA) photocoagulation of the episcleral 
and limbal veins two times with 7 days apart in the right eye. This technique was 
adopted from the method by WoldeMussie et al (WoldeMussie et al., 2001) and has 
been used in our laboratory with a track record of publications (Fu et al., 2008b; Fu et 
al., 2008a; Ji et al., 2004; Li et al., 2006b; Li et al., 2006a). About 90 spots were 
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applied on the three episcleral veins and 70 spots on the limbal vein (270° around the 
limbus, except on the nasal side) with the following settings: power of 1000 mW; spot 
size of 50 µm in diameter; and duration of 0.1s. The contralateral (left) eyes were used 
as controls. Animals were allowed to survive for 4 weeks post first laser exposure 
before they were sacrificed. The IOP of the eyes were measured using a Tonopen XL 
Tonometer (Mentor, Norwell, MA, USA) at different time points. 
The eyes with elevated IOP received intravitreal injection of proteins once a 
week in the 4-week glaucoma animals on day 0, 7, 14 and 21. The animals were 
divided into 4 groups, 0.01M phosphate buffered saline (PBS) group (2 µl), 
combination of BDNF (1 µg in 1 µl) and PBS (2 µl) group, LINGO-1-Fc group (2 µg 
in 2 µl), combination of BDNF (1 µg in 1 µl) and LINGO-1-Fc group (2 µg in 2 µl). 
The protein solution was injected intravitreally into the right eye using a 10 µl 
Hamilton microsyringe fixed with a 26-s gauge needle (#80300, Hamilton, Reno, 
Nevada, USA). The microsyringe was held inside the eyeball for more than 1 minute 
before being pulled out. The site of injection was just below of the limbus of the 
cornea, which provides minimal possibility of injury to the retina. The injections for 
combined proteins were performed at 30 min intervals. 
 
Retrograde labeling of RGCs and RGC counting 
In order to retrogradely label RGCs, both superior colliculi were exposed and a piece 
of Gelfoam (Pharmacia & Upjohn, NJ, USA) soaked with Fluoro-Gold (FG, 6% in 
distilled H2O, Fluorochrome, Denver, CO) was placed on the surface of superior 
colliculi seven days before sacrifice. At 4 weeks after laser coagulation, the rats were 
transcardially perfused with 0.9% saline for 30 min. Both eyes of each animal were 
enucleated and fixed in 4% paraformaldehyde for 60 min. Retinas were prepared as 
flat-mounts and the FG labeled RGCs were counted under fluorescence microscope 
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using an ultra-violet filter (excitation wave length = 330-380 nm). The RGCs were 
quantified under an eyepiece grid of 200 × 200 µm2 along the mid line of each 
quadrant, from the optic disc to the border at 500 µm intervals (Ji et al., 2004). Eight 
microscopic fields for each quadrant and a total of 32 per retina for four quadrants 
were counted. The data were expressed as the density of cells (number of cells/mm2) 
and also analyzed in terms of relative percent RGC loss in the injured right eye to the 
contralateral left intact eye from the same animal. 
 
Immunohistochemistry for TrkB and LINGO-1 
RGCs were retrogradely labeled with FG 7 days before sacrifice. The eyes were 
enucleated at 4 weeks after laser treatment following transcardial perfusion with 0.9% 
saline and were fixed in 4% paraformaldehyde for 1 h. After removing the cornea and 
lens, the eye cups were fixed further in paraformaldehyde for 4-6 h and then 
transferred to 30% sucrose solution at 4ºC for 16 h. The eye cups were embedded in 
OCT compound and cryosections (10 µm thick) were prepared at -20ºC. The retinal 
sections were washed with 0.01M PBS (PH 7.4), incubated in 0.5% Triton/PBS for 10 
min, and blocked with 10% normal goat serum and 0.1% Triton/PBS for 1 h. 
Incubation with mouse antibody for LINGO-1 (1:100, Biogen Idec, Inc. MA, USA) 
and chicken IgY TrkB antibody (1:100, Promega, Mannheim, Germany) was 
performed at 4ºC for 16 h. After washing with PBS, the sections were treated with 
Qdot@655 goat IgG anti-chicken IgY (1:400, Molecular probes, Oregon, USA) or 
Alexa-labeled goat anti-mouse 488 antibodies (1:400, Molecular probes, Oregon, 
USA) at room temperature for 2 h. After washing, the sections were mounted with 
fluorescent mounting medium (DakoCytomation, Denmark) and analyzed under Carl 
Zeiss LSM 510 META confocal microscope. We used the multi-photon laser (720 nm) 
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to excite the FG because this confocal microscope has no UV excitation laser. We 
regarded blue as the color of FG. The animal number was 4-5 for each group. 
?
Western blotting 
To measure the effects of BDNF and LINGO-1-Fc on TrkB phosphorylation, we 
injected recombinant human BDNF intravitreally (1 µg/injection) together with PBS 
(2µl) or BDNF together with LINGO-1-Fc (2 µg/injection) just after laser coagulation 
and then euthanized the animals 5 days later.  
Retinas were dissected and homogenized in lysis buffer (10 mM Tris pH7.4, 
150mM NaCl, 1mM EDTA, 1mM EGTA) supplemented with 10% protease inhibitor 
cocktail and 1% phosphatase inhibitor cocktails from Sigma. Following centrifugation 
at 13,000 rpm for 30 min to remove cell debris, the protein concentration of the 
supernatant was measured using a Bio-Rad DC protein Assay Kit (Bio-Rad 
Laboratories, CA, USA). A 80 µg aliquot of proteins from each sample was subjected 
to 6-10 % SDS-polyacrylamide gel electrophoresis and transferred onto PVDF 
membrane (Bio-Rad Laboratories, CA, USA). The membranes were blocked with 5% 
non fat dry milk and 2% bovine serum albumin (Sigma, MO, USA) in Tris-buffered 
saline containing 0.1% Tween 20 for 1 h in room temperature. Incubation with 
primary antibodies for phosphor-TrkB (p-TrkB, Tyr785, 1:100, a gift from Dr. B. Sun, 
Shanghai Institutes of Biological Sciences, Shanghai, China) (Ji et al., 2005) or 
chicken IgY total TrkB antibody (1:100, Promega, Mannheim, Germany) After 
washing, the membranes were incubated with Horseradish Peroxidas-conjugated goat 
anti-rabbit (1:2000, DakoCytomation, Denmark) or anti-IgY antibody (1:1000, 
Promega, Mannheim, Germany) in 5% non fat dry milk and 2% bovine serum 
albumin for 2 h at room temperature and immunoreactive proteins were detected 
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using the enhanced chemiluminescence method (Amersham, Piscataway, NJ, USA). 
The intensity of each band was quantified with densitometric scanning using 
Labworks gel documentation (UVP, Inc, Upland, CA). All experiments for western 
blotting were performed with 4-5 animals in each group and the samples from each 
animal were run on separate lanes. The levels of p-TrkB were finally expressed as 
relative values compared to total TrkB. 
?
Statistics 
The data were expressed as Mean ± SEM. Statistical analysis was performed by one-
way analysis of variance followed by post-hoc tests (Turkey HSD) for comparisons of 
more than two groups or using paired Student’s t test for comparisons between the 
right and contralateral left eyes in the same group. Data were analyzed statistically 
with the software SPSS 12.0. The mean difference is significant at 0.05 level. 
 
RESULTS?
Long-term RGC survival with the combined treatment of BDNF with 
LINGO-1 antagonist after ocular hypertension 
Our previous findings that LINGO-1 negatively regulates TrkB function suggest that 
BDNF may activate more TrkB after blocking the function of LINGO-1. To 
determine the long-term effect of BDNF on RGC survival, we induced chronic ocular 
hypertension in rats and examined RGC survival 4 weeks after the induction of 
elevated IOP. The right eyes received a total of 4 intravitreal injections of proteins. As 
reported in our previous study (Fu et al., 2008a), there was a significant loss of 20.9 ± 
1.2% RGCs at 4 weeks after laser coagulation in animals receiving PBS injection 
[1638 ± 32 cells per mm2 in experimental right eyes vs 2070 ± 59 cells per mm2 in left 
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control eyes; Paired Student t-test: paired differences, 431.8 ± 76.4, t (7) = 5.65, P = 
0.001] ( Fig. 1B). The treatment by  BDNF and LINGO-1-Fc resulted in a significant 
reduction of the RGC loss in experimental eyes (one-way analysis of variance , F3.28 = 
31.48, P < 0.0001). Consistent with previous report (Ko et al., 2001), four injections 
of BDNF only showed a partial neuroprotective effect on RGCs compared with PBS 
treatment group (P = 0.018, RGC loss, 15.3 ± 1.7%) (Fig. 1A). Combined treatments 
with BDNF and LINGO- 1-Fc rescued almost all of the RGCs compared with the 
BDNF+PBS group (P < 0.0001) and LINGO-1-Fc alone group (RGC loss, 8.8 ± 1.5%, 
P = 0.004) (Fig. 1A). Blocking the function of LINGO-1 with LINGO-1-Fc 
significantly reduced RGC loss compared with PBS group (P < 0.0001, Fig. 1A). 
However, there was still a significant RGC loss with the LINGO-1-Fc treatment alone 
[paired Student t-test between right and left eyes, t (7) = 2.431, P = 0.034] (Fig. 1B). 
In this study we also analyzed the data for RGC density between the treated eyes with 
normal eyes (Fig. 1C). Similar conclusions were drawn after using the normal eyes as 
the control. The administration of PBS and BDNF resulted in a significant loss for 
RGCs compared to normal group (P < 0.0001). After the treatment of LINGO-1-Fc 
alone, more RGCs survived compared to PBS and BDNF treated eyes (P < 0.0001). 
However, there was still RGC loss in LINGO-1-Fc group compared to normal group 
(P < 0.05). We have previously investigated the death of RGCs in our rat glaucoma 
model 2, 4, 8 and 12 weeks after laser coagulation. The results showed that the loss of 
RGCs reaches a maximal level after 4 weeks (Li et al., 2006a). So the findings of the 
significant neuroprotection of BDNF and LINGO-1-Fc in 4 weeks after laser 
coagulation provide sufficient evidence for the positive efficiency of LINGO-1-Fc 
and anti-LINGO-1 antibody in this glaucoma model. Representative 
photomicrographs of retinal flat-mount 4 weeks after ocular hypertension are shown 
in Fig. 1D. 
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IOP profile 
IOP in the contralateral left eye of treated animals remained at about the level of 13 
mmHg throughout the experiments. The IOP of the laser treated right eye in all groups 
increased after the first laser surgery and remained at the level of 23 mm Hg until 
sacrifice (Fig. 2). The treatments did not change the level of the IOP in treated rats 
compared with control animals. It suggests that RGC survival induced by combined 
BDNF/LINGO-1 treatments occurs in the face of maintained elevated IOP. 
 
TrkB Activation with the combined treatment of BDNF and LINGO-
1-Fc 
To reveal whether BDNF could activate TrkB more efficiently in the presence of 
LINGO-1-Fc. we injected exogenous BDNF into the eye and studied the TrkB 
activation 5 days after the induction of ocular hypertension (Fig. 3A, B). Normal rat 
retinas expressed total TrkB (lane 1-3). While p-TrkB level was very low in normal 
control retinas (lane 1-3). BDNF treatment alone increased p-TrkB levels but the 
change was not statistically significant (lane 4-6). However, BDNF combined with 
LINGO-1-Fc significantly increased p-TrkB levels under the same conditions (P = 
0.004 for LINGO-1-Fc compared to PBS group) (lane 7-9). This suggests that BDNF 
activates TrkB level after blocking the function of LINGO-1. These findings indicate 
that exogenous BDNF stimulation produced only limited activation of TrkB receptors 
but blocking of LINGO-1 function reversed this limitation. 
 
Co-localization of TrkB and LINGO-1 in the retinal ganglion cells 
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To further support the claim that LINGO-1-Fc supports BDNF to promote the 
activation of TrkB, we examined the co-localization of LINGO-1 and TrkB in the 
retina. The results presented in this study confirm our previous findings (Fu et al., 
2008a) that LINGO-1 was expressed in RGCs (Fig. 4A) and up-regulated after the 
induction of ocular hypertension (Fig. 4B). We found that there was moderate 
immunostaining for TrkB in the inner plexiform layer and in the ganglion cell layer in 
the normal retina (Fig. 4C). TrkB expression increased at 4 weeks after the induction 
of ocular hypertension (Fig. 4D). LINGO-1 and TrkB were co-expressed in the RGCs 
retrogradely labeled with FG (Fig. 4E-H).  
 
DISCUSSION 
Current neuroprotectants used to treat glaucoma only delay and do not prevent RGC 
death. This study showed that a combined treatment of BDNF and LINGO-1 
antagonist provides long term RGC neuroprotection after the induction of elevated 
IOP. We further identified that a combination of BDNF and LINGOO-1-Fc 
accelerates TrkB activation in the eyes with elevated IOP. Our study suggests an 
effective strategy for the treatment of glaucomatous neuropathy. 
 
Neuroprotective effects of combined application of BDNF and 
LINGO-1-Fc after ocular hypertension 
The loss of RGCs in patients suffering from glaucoma appears progressively over 
many years. An ideal neuroprotectant to treat glaucoma should enhance the survival 
of RGCs and preserve the function of RGCs without adverse effects on normal retinal 
signaling. Although numerous clinical trials in stroke, Parkinsonism and Alzheimer’s 
disease are underway, there are currently no clinical neuroprotectants that prevent 
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RGC death in human glaucoma. The major type of RGC death in glaucoma is 
probably apoptosis (Quigley et al., 1995). Neurotrophin can hinder the induction of 
apoptotic cell death and promote RGC survival. However, several neuroprotectants 
such as BDNF, neurotrophin-3 and 4, insulin-like growth factor, glial cell-derived 
neurotrophic factor show only partial protective effects on RGCs after retinal injury 
(Kermer et al., 2000; Klocker et al., 1997; Peinado-Ramon et al., 1996). Here we 
found that BDNF combined with LINGO-1-Fc resuced almost all of RGCs up to 4 
weeks after ocular hypertension. Unlike the slow course of human chronic glaucoma, 
the loss of RGCs in this rat ocular hypertension model becomes stable after 4 weeks 
(Li et al., 2006a). We have previously investigated the death of RGCs in our rat 
glaucoma model 2, 4, 8 and 12 weeks after laser coagulation. The results showed that 
the loss of RGCs reaches a maximal level after 4 weeks (Li et al., 2006a). The 
findings of the significant neuroprotection of combined treatment of BDNF and 
LINGO-1-Fc in 4-week course provide sufficient evidence for the positive efficiency 
of the combined treatment in this ocular hypertension model. 
The limited ability of BDNF to confer neuroprotection remains unresolved until 
now. The finding of long-term neuroprotection of combination of BDNF and LINGO-
1-Fc provides a clearer understanding of the activity of BDNF. Free radicals were 
suggested to responsible for limiting the rescue effect of BDNF after retinal injury 
(Klocker et al., 1998; Ko et al., 2000). However, a combined treatment of BDNF and 
antioxidants only showed partial survival of RGCs in the eyes of hypertensive rats 
(Ko et al., 2000). It is possible that the RGCs lose the responsiveness of TrkB to 
BDNF after retinal injury, as has been observed in other neurons (Carter et al., 1995; 
Frank et al., 1996). However, axotomized RGCs can express sufficient levels of TrkB 
(Di et al., 1998) and transferring the TrkB gene into RGCs combined with exogenous 
BDNF administration provided a transient increased neuronal survival after optic 
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nerve transection (Cheng et al., 2002).  Here we found that the  limited protection of 
BDNF on RGCs could be reversed after blocking of LINGO-1 function. We further 
identified a possible mechanism underlying this protective effect, as described in the 
following discussion. 
We previously found that blocking LINGO-1 function promoted RGC survival 
in a rat ocular hypertenstion model. However, there was still some RGC loss at 4 
weeks after the induction of ocular hypertension. In this study we found that the effect 
of a combined treatment of BDNF and LINGO-1-Fc on RGC survival in this animal 
model of ocular hypertension is better than LINGO-1-Fc alone. It suggests LINGO-1-
Fc has limited neuroprotection. 
 
The effect of combined application of BDNF and LINGO-1-Fc on 
TrkB activation after ocular hypertension 
Here we found that a combined treatment of BDNF and LINGO-1-Fc could activate 
more TrkB compared to BDNF alone. Neurotrophins can activate two types of 
receptors, the Trk family and p75 receptor (Huang and Reichardt, 2003). Trk 
receptors consist of a family of three receptor tyrosine kinases, TrkA, TrkB and TrkC, 
each of which can be activated by respective neurotrophins. TrkB is the dominant Trk 
receptors in the retina. BDNF exerts its neuroprotective activity by activating TrkB. 
The p-TrkB subsequently activates the downstream signaling pathway such as PI-
3K/Akt (Huang and Reichardt, 2003). These data suggest that LINGO-1 may 
negatively regulate the activity of BDNF and TrkB. We just identified that LINGO-1 
binds with TrkB and negatively regulates its activation in a culture system of RGCs 
and in the retina of rats (Fu QL et al., unpublished data). These data suggest a possible 
molecular mechnism that the partial neuroprotection of BDNF may largely 
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attributable to negative regulation of LINGO-1 to the BDNF-TrkB signaling receptor.   
It may be the novel molecular mechanism that a combination of BDNF with LINGO-
1 antagonists promotes long-term survival on RGCs in this model of ocular 
hypertension. We found that LINGO-1-Fc as a soluble protein of LINGO-1 directly 
binds on the surface of LINGO-1 to block its function (data now shown). The 
involved signal pathways is described in Figure 5. 
 
CONCLUSIONS 
The marked neuroprotection of a combined treatment of BDNF and LINGO-1-Fc in 
4-week course has important significance for the long-term prevention of RGC 
damage in this glaucoma model. The application of BDNF combined with LINGO-1 
antagonists leads to a long term protection for RGCs in this chronic hypertension 
model. It provides a new avenue to combat RGC death after chronic retinal injury. 
Neurotrophins are being tested currently in clinical trials for the treatment of various 
neurological disorders. If our observations obtained in RGCs can be extended to other 
neuronal populations and injury paradigms, the use of LINGO-1 antagonists may 
provide a promising way to optimize the neuroprotective effects of neurotrophins. 
This could help in designing new strategies in the treatment of human 
neurodegenerative diseases.  
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 Figure Legends 
 
Figure 1. Blocking of LINGO-1 function reinforces the neuroprotective activity 
of BDNF after ocular hypertension 
(A) Percentage of RGC loss in the hypertensive eyes at 4 weeks post laser coagulation 
(Mean ± SEM). BDNF exhibits a slight neuroprotection to injured RGCs (* P = 0.018 
compared to PBS group). Blocking the function of LINGO-1 with LINGO-1-Fc 
significantly reduced RGC loss (*** P < 0.0001 compared to PBS group). A 
combined administration of BDNF and LINGO-1-Fc rescued almost all of the RGCs 
compared to BDNF (*** P < 0.0001) and LINGO-1-Fc (** P = 0.004) alone in this 
ocular hypertension model. n = 8 for each group. (B) Analyses for the density of 
RGCs between the right eyes and left eyes in each group (the number of RGCs/mm2, 
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Mean ± SEM). Paired Student’s t test was used to analyze the data. There was loss of 
RGCs in right eyes compared to left eyes in PBS [t (7) =5.65, ** P = 0.001] and 
BDNF [t (7) = 9.611, *** P < 0.0001] groups. The application of LINGO-1-Fc 
showed slight RGC loss [t (7) = 2.431, * P = 0.045] after laser coagulation. However, 
the combined treatment of BDNF and LINGO-1-Fc rescued almost all the RGCs after 
a long-term progress of 4 weeks following the induction of ocular hypertension [t (7) 
= 1.161, P = 0.284]. (C) The data were analyzed with RGC density between 
experimental eyes and normal eyes. (D) Flat-mounted retinas showing surviving 
Fluoro-Gold labeled RGCs 4 weeks after laser coagulation with different treatments. 
 
Figure 2. IOP profile after induction of ocular hypertension. The IOP of 
experimental right eyes was significantly elevated after the first laser treatment 
compared with those of control left eyes for each group. The elevated IOP remained at 
a steady level throughout the experimental period. The treatments did not reduce IOP. 
IOP values are expressed as the Mean ± SEM. 
 
Figure 3. Combined treatment of BDNF and LINGO-1-Fc increases TrkB 
activation. (A) Western blots of p-TrkB and total TrkB in the retinas at 5 days after 
laser coagulation with the treatment of BDNF alone (lane 4-6) or combined with 
LINGO-1-Fc (lane 7-9). (B) Densitometric scanning of p-TrkB quantity in western 
blotting presented in the upper panel showed a significant elevation of p-TrkB levels 
with the combined treatment of BDNF and LINGO-1-Fc (lane 7-9) compared with 
BDNF treatment alone (lane 4-6) (P < 0.01). The relative p-TrkB level was calculated 
by the value of p-TrkB over the value of total TrkB. Each band stands for an 
individual animal. P values compared to normal and BDNF groups. n = 3 for each 
group (Mean ±  SEM). 
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Figure 4. LINGO-1 is coexpressed with TrkB in the retinal ganglion cells. 
Representative photomicrographs of LINGO-1 and TrkB expression in normal and 
injured retina following 4 weeks ocular hypertension. TrkB staining (red) (A,B), 
LINGO-1 staining (green) (C,D), retrograde Fluoro-Gold (FG) labeled RGCs (blue) 
(E,F) demonstrates the co-localization of LINGO-1 and TrkB in RGCs (magenta) 
(arrows) (G,H). The expression of TrkB and LINGO-1 increased after the induction of 
ocular hypertension. GCL: ganglion cell layer. INL: inner nuclear layer; ONL: outer 
nuclear layer. FG: Fluoro-Gold. 
 
Figure 5. The diagram of the signaling pathways involved in the combined 
neuroprotection of BDNF and LINGO-1-Fc on RGCs after the inductin of ocular 
hypertension. In the normal condition, LINGO-1 binds with TrkB and negatively 
modulates the activity of TrkB. Elevated IOP increased the level of LINGO-1. The 
activation of TrkB is not sufficient and results in transient RGC protection after the 
application of exogenous BDNF. LINGO-1-Fc relieves the limitation of LINGO-1 to 
TrkB. A combination of BDNF and LINGO-1-Fc activates more TrkB and finally 
promotes long-term RGC survival.  
?
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